Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Nuclear Medicine and Molecular Imaging
Published in: Nuclear Medicine and Molecular Imaging 2/2021

01-04-2021 | Magnetic Resonance Imaging | Interesting image

False-Positive Gallium-68 DOTATATE PET/CT in Vertebral Hemangioma

Authors: Ahmed Abdulrahman Alruwaili, Alaa Khalid Alduraibi, Mohammed Fahed Alzayed

Published in: Nuclear Medicine and Molecular Imaging | Issue 2/2021

Login to get access

Abstract

A healthy 52-year-old man started to have few minutes spells of palpitation, tachycardia, hot flashes, and chest tightness. He had a lab work-up for carcinoid, including 5-hydroxyindoleacetic acid (5-HIAA), which was negative. Months later, his symptoms became worse which warranted further investigation to exclude carcinoid disease. Gallium-68 DOTATATE positron emission tomography combined with computed tomography (PET/CT) scanning was performed to assess the patient for carcinoid tumor. It showed foci of radiotracer avidity in the thoracic and lumber spine. Magnetic resonance imaging (MRI) for the vertebral lesions showed atypical hemangioma. Subsequently, follow-up serum chromogranin A testing was negative.
Literature
1.
Krenning EP, Breeman WA, Kooij PP, Lameris JS, Bakker WH, Koper JW, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;333:242–4.CrossRef
2.
Vanhagen PM, Krenning EP, Reubi JC, et al. Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med. 1994;21:497Y502.CrossRef
3.
Ross EM, Roberts WC. The carcinoid syndrome: comparison of 21 necropsy subjects with carcinoid heart disease to 15 necropsy subjects without carcinoid heart disease. Am J Med. 1985;79:339–54.CrossRef
4.
Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer. 2005;12:1083–92.CrossRef
5.
Skoura E, Michopoulou S, Mohmaduvesh M, Panagiotidis E, Al Harbi M, Toumpanakis C, et al. The impact of 68Ga-DOTATATE PET/CT imaging on management of patients with neuroendocrine tumors: experience from a national referral center in the United Kingdom. J Nucl Med. 2016;57:34–40.CrossRef
6.
Albanus DR, Apitzsch J, Erdem Z, Erdem O, Verburg FA, Behrendt FF, et al. Clinical value of 68Ga-DOTATATE-PET/CT compared to stand-alone contrast enhanced CT for the detection of extra-hepatic metastases in patients with neuroendocrine tumours (NET). Eur J Radiol. 2015;84:1866–72.CrossRef
7.
Putzer D, Gabriel M, Henninger B, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA- Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009:1214–21.
8.
Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B, et al. 68 Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med. 2013;40:514–23.CrossRef
9.
Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. QJ Nucl Med Mol Imag. 2010;54:61–7.
10.
Skoura E, Alshammari A, Syed R, Sajjan R, Bomanji J. Adolescent with 68Ga DOTATATE-avid vertebral hemangioma mimicking metastasis in PET imaging. Clin Nucl Med. 2015;40:e378–9.CrossRef
11.
Gauthé M, Dardel NT, Santiago FR, Ohnona J, Nataf V, Montravers F, et al. Vertebral metastases from neuroendocrine tumours: how to avoid false positives on 68 Ga-DOTA-TOC PET using CT pattern analysis? Eur Radiol. 2018;28:3943–52.CrossRef
Metadata
Title
False-Positive Gallium-68 DOTATATE PET/CT in Vertebral Hemangioma
Authors
Ahmed Abdulrahman Alruwaili
Alaa Khalid Alduraibi
Mohammed Fahed Alzayed
Publication date
01-04-2021
Publisher
Springer Singapore
Published in
Nuclear Medicine and Molecular Imaging / Issue 2/2021
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-021-00682-x

Other articles of this Issue 2/2021

Nuclear Medicine and Molecular Imaging 2/2021 Go to the issue

Original Article

Development of GATE Monte Carlo Code for Simulation and Dosimetry of New I-125 Seeds in Eye Plaque Brachytherapy

Review

A Review of Neuroimaging Studies in Persistent Postural-Perceptual Dizziness (PPPD)

Correction

Correction to: Recent Progress in the Molecular Imaging of Tumor-Treating Bacteria

Case Report

Hilar Choledochal Cyst Mimicking Biliary Atresia on Hepatobiliary Scintigraphy: a Case Report

Review

Nuclear Imaging for Cardiac Amyloidosis: Bone Scan, SPECT/CT, and Amyloid-Targeting PET

Original Article

A 4-Year Follow-Up of Subjects with Visually Equivocal Amyloid Positron Emission Tomography Findings from the Alzheimer’s Disease Neuroimaging Initiative Cohort